Back to top
more

BondBloxx Bloomberg One Year Target Duration US Treasury ETF: (XONE)

(Delayed Data from NYSE) As of Feb 25, 2026 04:00 PM ET

$49.60 USD

49.6
563,378

-0.01 (-0.02%)

Volume: 563,378

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

Zacks News

Zacks Equity Research

Immersion (IMMR) to Report Q4 Earnings: What's in Store?

Though Immersion's (IMMR) Q4 revenues might have been negatively impacted by the pandemic, efficient cost management is likely to have aided the bottom line.

Zacks Equity Research

Daqo New Energy (DQ) to Post Q4 Earnings: What's in the Cards?

Daqo New Energy's (DQ) fourth-quarter results are expected to reflect the benefits of higher production and sales volumes.

Zacks Equity Research

ExOne (XONE) Soars 24.3%: Is Further Upside Left in the Stock?

ExOne (XONE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

ExOne (XONE) Reports Q3 Loss, Tops Revenue Estimates

ExOne (XONE) delivered earnings and revenue surprises of 5.00% and 37.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ExOne (XONE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

ExOne (XONE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ExOne (XONE) Looks Good: Stock Adds 5.7% in Session

ExOne (XONE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne

Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne

Zacks Equity Research

Sealed Air (SEE) Stock Down 18% YTD: Will it Bounce Back?

Sealed Air's (SEE) end markets are bearing the brunt of coronavirus pandemic. However, the company's restructuring actions will help negate the impact.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

ExOne (XONE) Reports Q1 Loss, Tops Revenue Estimates

ExOne (XONE) delivered earnings and revenue surprises of 26.67% and 16.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?